These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16114994)

  • 1. A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma.
    Lindén O; Kurkus J; Garkavij M; Cavallin-Ståhl E; Ljungberg M; Nilsson R; Ohlsson T; Sandberg B; Strand SE; Tennvall J
    Cancer Biother Radiopharm; 2005 Aug; 20(4):457-66. PubMed ID: 16114994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biotinylation, pharmacokinetics, and extracorporeal adsorption of humanized MAb 111In-MN14 using an avidin-affinity column in rats.
    Wang Z; Garkavij M; Ohlsson T; Strand SE; Sjögren HO; Tennvall J
    Cancer Biother Radiopharm; 2003 Jun; 18(3):365-75. PubMed ID: 12954123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.
    Muylle K; Flamen P; Vugts DJ; Guiot T; Ghanem G; Meuleman N; Bourgeois P; Vanderlinden B; van Dongen GA; Everaert H; Vaes M; Bron D
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1304-14. PubMed ID: 25792453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
    Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
    Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.
    Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
    Cancer; 2010 Feb; 116(4 Suppl):1043-52. PubMed ID: 20127949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of extracorporeal immunoadsorption to reduce circulating blood radioactivity after intraperitoneal administration of indium-111-HMFG1-biotin.
    Wang Z; Garkavij M; Tennvall JG; Ohlsson T; Strand SE; Sjögren HO
    Cancer; 2002 Feb; 94(4 Suppl):1287-92. PubMed ID: 11877758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pharmacokinetics of various monoclonal antibodies labeled with a new trifunctional chelating reagent for simultaneous conjugation with 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid and biotin before radiolabeling.
    Wang Z; Mårtensson L; Nilsson R; Bendahl PO; Lindgren L; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7171s-7177s. PubMed ID: 16203818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
    Breitz HB; Fisher DR; Goris ML; Knox S; Ratliff B; Murtha AD; Weiden PL
    Cancer Biother Radiopharm; 1999 Oct; 14(5):381-95. PubMed ID: 10850323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
    Shen S; Forero A; Meredith RF; Shah JJ; Knox SJ; Wiseman GA; Usrey ME; Lobuglio AF
    J Nucl Med; 2010 Jan; 51(1):150-7. PubMed ID: 20008989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.
    Forero-Torres A; Shen S; Breitz H; Sims RB; Axworthy DB; Khazaeli MB; Chen KH; Percent I; Besh S; LoBuglio AF; Meredith RF
    Cancer Biother Radiopharm; 2005 Aug; 20(4):379-90. PubMed ID: 16114986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.
    Weiden PL; Breitz HB; Press O; Appelbaum JW; Bryan JK; Gaffigan S; Stone D; Axworthy D; Fisher D; Reno J
    Cancer Biother Radiopharm; 2000 Feb; 15(1):15-29. PubMed ID: 10740649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
    Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
    J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
    Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
    Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biocompatibility of a novel avidin-agarose adsorbent for extracorporeal removal of redundant radiopharmaceutical from the blood.
    Kurkus J; Nilsson R; Lindén O; Schönström N; Sandberg BE; Tennvall J
    Artif Organs; 2007 Mar; 31(3):208-14. PubMed ID: 17343696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies.
    Nemecek ER; Green DJ; Fisher DR; Pagel JM; Lin Y; Gopal AK; Durack LD; Rajendran JG; Wilbur DS; Nilsson R; Sandberg B; Press OW
    Cancer Biother Radiopharm; 2008 Apr; 23(2):181-91. PubMed ID: 18454687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma.
    Gholipour N; Jalilian AR; Khalaj A; Johari-Daha F; Yavari K; Sabzevari O; Khanchi AR; Akhlaghi M
    Daru; 2014 Jul; 22(1):58. PubMed ID: 25074720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion.
    Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
    J Nucl Med; 2007 Feb; 48(2):269-76. PubMed ID: 17268025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change in tumor-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients.
    Hindorf C; Lindén O; Stenberg L; Tennvall J; Strand SE
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):4003S-6S. PubMed ID: 14506200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
    Frost SH; Frayo SL; Miller BW; Orozco JJ; Booth GC; Hylarides MD; Lin Y; Green DJ; Gopal AK; Pagel JM; Bäck TA; Fisher DR; Press OW
    PLoS One; 2015; 10(3):e0120561. PubMed ID: 25785845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.